The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
Yoichi Naito
Honoraria - Eisai
Akira Kawai
Expert Testimony - Eisai
Nobuhito Araki
No relevant relationships to disclose
Toshifumi Ozaki
Honoraria - Eisai
Hideshi Sugiura
No relevant relationships to disclose
Yasuo Yazawa
No relevant relationships to disclose
Hideo Morioka
Honoraria - Eisai
Research Funding - Eisai
Akihiko Matsumine
No relevant relationships to disclose
Masahide Hiraiwa
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Shun Asami
Employment or Leadership Position - Eisai
Honoraria - Eisai
Kazuo Isu
Consultant or Advisory Role - Eisai